Neostigmine methyl sulfate , 98% , 51-60-5
Synonym(s):
3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate
CAS NO.:51-60-5
Empirical Formula: C12H19N2O2.CH3O4S
Molecular Weight: 334.39
MDL number: MFCD00011796
EINECS: 200-109-5
Pack Size | Price | Stock | Quantity |
1G | RMB131.20 | In Stock |
|
5G | RMB364.80 | In Stock |
|
25g | RMB1399.20 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 175-177 °C(lit.) |
storage temp. | -20°C |
solubility | H2O: 1 g/mL |
form | powder |
color | white |
Water Solubility | 1g/10mL |
Merck | 14,6464 |
CAS DataBase Reference | 51-60-5(CAS DataBase Reference) |
Description and Uses
Neostigmine is a reversible inhibitor of acetylcholinesterase (AChE; Kd = 260 μM). In a rat model of knee joint inflammation, intrathecal administration of neostigmine (2-30 μg) increases endogenous acetylcholine levels and dose-dependently increases the latency of paw withdrawal in response to thermal and mechanical stimuli (ED50s = 6.6 and 3.5 μg, respectively). Neostigmine (5 μg, i.p.) restores muscle action potentials in mice with a thymopoietin-induced neuromuscular block. Formulations containing neostigmine have been used in the treatment of myasthenia gravis and Ogilvie syndrome.
Cholinergic; miotic; antidote (curare)
Safety
Symbol(GHS) | GHS06,GHS08 |
Signal word | Danger |
Hazard statements | H300-H315-H319-H334-H335 |
Precautionary statements | P261-P284-P301+P330+P331+P310-P304+P340-P305+P351+P338-P342+P311 |
Hazard Codes | T+ |
Risk Statements | 28-36/37/38-42/43-26/27/28 |
Safety Statements | 36-45-36/37/39-28A |
RIDADR | UN 2811 6.1/PG 2 |
WGK Germany | 3 |
RTECS | CY1225000 |
HazardClass | 6.1(a) |
PackingGroup | II |
HS Code | 29242990 |
Toxicity | LD50 in mice (mg/kg): 0.16 i.v.; 0.42 s.c.; 7.5 orally, (Randall, Lehmann) |